Browsing: Insilico

China’s speed, scale and infrastructure are central to Insilico’s ambition to build a ‘digital Einstein’ for faster, cheaper drug discovery.…

Insilico Medicine IPO signals that AI‑native drug discovery is moving from promise to public markets with a central longevity narrative.…

A 3D virtual model of the PKMYT1–PROTAC–CRBN ternary complex depicting how Insilico Medicine’s bifunctional proteolysis-targeting chimera (PROTAC) D16-M1P2 (shown in…

Pharma giant Lilly strengthens ties with Insilico Medicine to accelerate AI-driven drug development and reshape discovery timelines. Insilico Medicine has…

A corridor at Insilico Medicine’s Robotics Lab in Suzhou, China. Insilico will partner with Eli Lilly on an artificial intelligence…

Generative AI biotech unveils portfolio of novel cardiometabolic candidates aimed at tackling the biology of aging. Insilico Medicine has announced…